These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32656933)

  • 1. Localized leishmaniasis treated with intralesional meglumine antimoniate.
    Villela-Segura U; Proy-Trujillo H; Ilizaliturri-Flores I; Leal-Ascencio VJ; Eljure-López N
    J Dtsch Dermatol Ges; 2020 Sep; 18(9):1025-1027. PubMed ID: 32656933
    [No Abstract]   [Full Text] [Related]  

  • 2. Intralesional injections of meglumine antimoniate to treat complex facial leishmania infantum acquired in Spain: a case report.
    Mostmans Y; Van Gysel J; Vanden Nest H; Mervillie K; Richert B; Clevenbergh P
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e548-e550. PubMed ID: 35181939
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series.
    Arboleda M; Barrantes S; Úsuga LY; Robledo SM
    Rev Soc Bras Med Trop; 2019 May; 52():e20180211. PubMed ID: 31141044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
    Duque MC; Vasconcellos ÉC; Pimentel MI; Lyra MR; Pacheco SJ; Marzochi MC; Rosalino CM; Schubach AO
    Rev Soc Bras Med Trop; 2016; 49(6):774-776. PubMed ID: 28001228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrocardiographic Alterations Related to Intralesional Glucantime® Treatments: A Potentially Severe Adverse Event.
    García Bracamonte B; Burillo Martínez S; Morales Raya C; Ortiz Romero P
    Actas Dermosifiliogr; 2022; 113(7):742-744. PubMed ID: 35331726
    [No Abstract]   [Full Text] [Related]  

  • 6. Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B.
    Spinicci M; Zammarchi L; Gramiccia M; Di Muccio T; Bartolozzi D; Corsi P; Trotta M; Bartoloni A
    J Travel Med; 2021 Aug; 28(6):. PubMed ID: 32918547
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
    Faghihi G; Tavakoli-kia R
    Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.
    Aste N; Pau M; Ferreli C; Biggio P
    Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904
    [No Abstract]   [Full Text] [Related]  

  • 9. Weekly vs. fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis.
    Mujtaba G; Khalid M
    Int J Dermatol; 1999 Aug; 38(8):607-9. PubMed ID: 10487452
    [No Abstract]   [Full Text] [Related]  

  • 10. Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities.
    Pimentel MIF; Vasconcellos ÉCFE; Ribeiro CO; Lyra MR; Saheki MN; Salgueiro MM; Antonio LF; Schubach AO
    Rev Soc Bras Med Trop; 2017; 50(2):269-272. PubMed ID: 28562769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns.
    Aronson NE; Billick K
    Clin Infect Dis; 2023 Aug; 77(4):583-588. PubMed ID: 37185765
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z; Nakhli A; Rassaii S
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract]   [Full Text] [Related]  

  • 13. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
    Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
    Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
    Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T
    Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma antimony determination during cutaneous leishmaniasis treatment with intralesional infiltration of meglumine antimoniate.
    de Aguiar MG; Gonçalves JE; Souza MD; de Silva RE; Silveira JN; Cota G
    Trop Med Int Health; 2018 Oct; 23(10):1110-1117. PubMed ID: 30053341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
    Bogenrieder T; Lehn N; Landthaler M; Stolz W
    Dermatology; 2003; 206(3):269-72. PubMed ID: 12673089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis.
    Asilian A; Sadeghinia A; Faghihi G; Momeni A; Amini Harandi A
    Ann Trop Med Parasitol; 2003 Jul; 97(5):493-8. PubMed ID: 12930612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Localized Cutaneous Leishmaniasis With Intralesional Meglumine Antimoniate and Photodynamic Therapy.
    Costin A; Bonito F; Alves J; Barreiros H
    Actas Dermosifiliogr (Engl Ed); 2020 Dec; 111(10):897-899. PubMed ID: 32473104
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis.
    Asilian A; Sadeghinia A; Faghihi G; Momeni A
    Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial.
    Machado PRL; Ribeiro CS; França-Costa J; Dourado MEF; Trinconi CT; Yokoyama-Yasunaka JKU; Malta-Santos H; Borges VM; Carvalho EM; Uliana SRB
    Trop Med Int Health; 2018 Sep; 23(9):936-942. PubMed ID: 29924907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.